May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension

Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in 2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018 campaign was expanded, aiming to include more participants and countries. Methods and results Eighty-nine countries participated in MMM 2018. Volunteers (≥18 years) were recruited through opportunistic sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire on demographic, lifestyle, and environmental factors. Hypertension was defined as a systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, or taking antihypertensive medication. In total, 74.9% of screenees provided three BP readings. Multiple imputation using chained equations was used to impute missing readings. 1 504 963 individuals (mean age 45.3 years; 52.4% female) were screened. After multiple imputation, 502 079 (33.4%) individuals had hypertension, of whom 59.5% were aware of their diagnosis and 55.3% were taking antihypertensive medication. Of those on medication, 60.0% were controlled and of all hypertensives, 33.2% were controlled. We detected 224 285 individuals with untreated hypertension and 111 214 individuals with inadequately treated (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) hypertension. Conclusion May Measurement Month expanded significantly compared with 2017, including more participants in more countries. The campaign identified over 335 000 adults with untreated or inadequately treated hypertension. In the absence of systematic screening programmes, MMM was effective at raising awareness at least among these individuals at risk

Le projet Jurismart : une recherche interdisciplinaire sur les réseaux énergétiques intelligents

International audienc

Dysfonction érectile et traitement antihypertenseur : impact des différentes classes thérapeutiques et conduite à tenir à l’égard du traitement

International audienceErectile dysfunction (ED) is not routinely discussed with patients in cardiology practices whereas it may impact the ability of patients to stay on therapy. Most of the studies about ED and antihypertensive therapies have several methodological limitations. Diuretics and beta-blockers have been shown to have a deleterious effect on ED. ISRA inhibitors, calcium antagonists, vasodilator beta-blockers and alpha-blockers have been shown to have a neutral impact on ED. Angiotensin 2 inhibitors, nebivolol and alpha-blockers use has sometimes beneficial effect on ED. In case of ED due to antihypertensive treatment, drugs can be switched each other but careful attention in patients with a high cardiovascular risk is required.La dysfonction érectile (DE) est un effet indésirable des traitements antihypertenseurs trop peu abordé en consultation et est source de mauvaise observance.L’évaluation du lien possible entre traitement antihypertenseur et DE reste imparfaite dans la littérature, fonction des populations étudiées et des méthodes d’évaluation de celle-ci.Les diurétiques et certains bêtabloquants semblent contribuer à la DE.Les bloqueurs du système rénine angiotensine, les inhibiteurs calciques, certains bêtabloquants vasodilatateurs et les alphabloquants semblent neutres sur la DE.Les inhibiteurs de l’angiotensine 2, le nébivolol, et les alphabloquants ont parfois une action favorable sur la DE.Le chemin clinique pour la prise en charge de la DE propose en sa présence de modifier le traitement antihypertenseur, mais sous certaines conditions chez le patient à haut risque cardiovasculaire